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Abstract 
Background: Type II diabetes is an important health problem with a complex connection to obesity, leading to a 
broad range of cardiovascular complications. Insulin therapy often results in weight gain and does not always ensure 
adequate glycemic control. However, previous studies reported that insulin detemir is an efficient long‑acting insulin 
with a weight sparing effect. The aim of this study was to determine the association of catechol O‑methyltransferase 
(COMT) Val108/158Met and dopamine‑beta‑hydroxylase (DBH) 1021C/T polymorphisms with the effectiveness 
of insulin detemir in achieving glucose control and body weight control. Participants and methods: This 52‑week 
observational study included 185 patients with inadequate glycemic control treated with premix insulin analogues, 
which were replaced with insulin aspart and insulin detemir, and 156 healthy controls. After DNA isolation from blood 
samples, genotyping of DBH‑1021C/T polymorphism (rs1611115) and COMT Val108/158Met polymorphism (rs4680) 
was performed.
Results: Our results confirmed that insulin detemir did not lead to weight gain. The most significant finding was that 
A carriers (the combined AG and AA genotype) of the COMT Val108/158Met achieved significantly better hemoglobin 
A1c (HbA1c) values compared to patients carrying GG genotype. No association between DBH‑1021C/T genotypes 
and weight and/or glucose control was detected in diabetes patients or in healthy control subjects.
Conclusions: This study showed that the presence of one or two A allele of the COMT Val108/158Met was associ‑
ated with improved glycemic response, and with a better response to insulin detemir therapy in patients with type II 
diabetes, separating them as best candidates for detemir therapy.
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Background
Type II diabetes (T2DM) represents an important health 
problem, affecting a substantial percentage of the world 
population. It is designated by a chronic progressive 
course and a subsequent need for a long-term insulin 
therapy to achieve optimal glucose control. Achieving 
the recommended target values can prevent complica-
tions and improve outcomes of diabetes. Still, a substan-
tial number of T2DM patients do not achieve optimal 
glucose control despite intensive insulin treatment [1]. 
International studies of T2DM patients have shown that 
many patients fail to achieve hemoglobin A1c (HbA1c) 
target values [2].
Obesity and diabetes
The increase in the prevalence of T2DM in recent dec-
ades parallels the rise in obesity [3]. Obesity is associated 
with an increased risk of developing insulin resistance, 
which combined with inappropriate β-cells compensa-
tory mechanisms may lead to T2DM [4]. However, the 
interplay between diabetes and obesity harbors a much 
more complex correlation. Insulin therapy often leads 
to weight gain and the concern is that 80–90% of T2DM 
patients are already obese before insulin treatment [5]. 
Weight gain increases the risk of coronary heart disease 
and cardiovascular complications in people with diabe-
tes [6]. Glucose homeostasis and insulin production are 
greatly determined by obesity and body fat distribution, 
however the pathogenesis of obesity-induced insulin 
resistance has not been fully elucidated [7]. Growing evi-
dence suggests that nutrients and hormonal signals con-
verge and directly act on brain centers, leading to changes 
in energy metabolism and stable body weight over time 
[8]. There is evidence suggesting that these same signals 
act on the central nervous system (CNS) to regulate glu-
cose metabolism independently [8].
Dopamine‑beta‑hydroxylase (DBH)
Several neurotransmitters, such as dopamine, gamma-
aminobutyric acid (GABA), serotonin and norepineph-
rine, as well as peptides and amino acids, are involved in 
the CNS’s regulation of energy and glucose homeostasis 
and in food intake regulation [9]. Dopamine is involved 
in weight regulation and food intake: it modulates dif-
ferent physiological functions including salt metabolism, 
which is associated with weight gain. Dopamine-beta-
hydroxylase (DBH) is an enzyme localized within 
secretory vesicles of norepinephrine and epinephrine 
producing neurons and neurosecretory cells, where it 
catalyzes the conversion of dopamine to norepinephrine 
[10]. It has been shown that several DBH gene polymor-
phisms influence the DBH plasma activity [11] including 
DBH-1021C/T functional polymorphism that accounts 
for 35–52% of the inter-individual variations in plasma 
DBH activity [10–12]. Plasma DBH activity is under the 
genetic control of a single-nucleotide polymorphism 
(SNP), DBH-1021C/T, in the 5′ flanking region of the 
DBH gene. In this context T-allele is associated with 
reduced DBH plasma activity, in comparison to C-allele 
[10, 12]. For many years now, scientists are connecting 
the DBH enzyme activity with diabetes and other high 
risk phenotypes, but the underlying mechanisms are not 
yet fully elucidated [13, 14]. However, it is known that 
DBH knock down mice are presenting with an impaired 
glucagon response to hypoglycemia and elevated insulin 
levels [14].
Catechol O‑methyltransferase (COMT)
Catechol O-methyltransferase is one of the major 
enzymes involved in catecholamine and estrogen deg-
radation [15]. Given the fact that both catecholamines 
and estrogen are associated with changes in metabolism 
and food intake, it is not surprising that changes of this 
enzyme may participate in the weight gain [16]. COMT 
is an important modulator in the catabolism of extra-
neural dopamine [17]. COMT removes toxic metabolites 
from the body, and regulates blood pressure via cat-
echolamine metabolism. Changes in the COMT activity, 
associated with genetic variants in the COMT gene have 
consequences in various mechanisms connected with 
development of obesity, personality changes and behav-
ior disturbances [18–22]. The most investigated poly-
morphism of the COMT gene, COMT Val108/158Met, 
consists of G-to-A transition on positions 158 or 108 of 
the COMT gene leading to the replacement of the amino 
acid valine (Val) with the amino acid methionine (Met) 
[23, 24]. This polymorphism is associated with a three- 
to fourfold variation in the COMT enzyme activity, with 
the Val (G) allele displaying higher and the Met (A) allele 
lower enzymatic activity [25, 26]. There is a well-estab-
lished association between the COMT Val108/158Met 
polymorphism and abdominal obesity and blood pres-
sure increase [27], human hypertension [28], and T2DM 
[29].
Therapeutic challenges
The number of treatment options for T2DM has 
increased over the past two decades. As the understand-
ing of the underlying pathophysiological mechanisms 
in T2DM increases, pharmacological possibilities have 
expanded to target novel physiologic mechanisms [30]. 
In spite of the above mentioned, many patients remain 
uncontrolled and the effectiveness of current therapies 
wanes over time [4]. There is also the problem of weight 
gain due to insulin therapy. Basal insulins are used to 
suppress uncontrolled hepatic glucose production and 
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therefore have to be relatively long-acting. One of those 
long-acting insulins is detemir. Besides a low pharmaco-
dynamic coefficient of variability [31], it exhibits anorexi-
genic features, probably through a complex interplay of 
its effects on the CNS [32] and on the finely tuned effer-
ent and afferent signals between muscle, brain, liver, renal 
and adipose tissues [33].
Aim
Compared to other basal insulins, patients treated with 
insulin detemir had reduced weight gain, which could 
be due to reduced energy intake rather than increased 
energy expenditure [34]. The aim of this study was to 
determine the association of COMT Val108/158Met 
and DBH-1021C/T polymorphisms with effectiveness 
of insulin detemir in achieving glucose control as well as 
body weight control.
Methods
Patients and control subjects
This 52-week observational monocentric study was con-
ducted at the University Clinic for Diabetes, Endocri-
nology and Metabolic Diseases Vuk Vrhovac, Zagreb, 
Croatia. The study included 185 (70 male, 115 female) 
patients diagnosed with type 2 diabetes aged 20–80 years 
with inadequate glycemic control [HbA1c level from 
7 to 11% (53–97  mmol/mol)] on a retrospective docu-
mented treatment with premix insulin analogues and 156 
(52 male, 104 female) healthy control subjects, sampled 
during their routine laboratory check-ups. All subjects 
were Caucasians of Croatian origin. Patients treated with 
antipsychotic medications, those who had clinically sig-
nificant gastroparesis, an end stage renal disease, severe 
chronic pancreatitis, a severe liver dysfunction with por-
tal hypertension or cirrhosis, an inflammatory bowel 
disease (Crohn’s disease, ulcerative colitis), unregulated 
hypothyroidism or hyperthyroidism, a known malignant 
disease, who underwent bariatric surgery, or with a his-
tory of drug or alcohol abuse were not included in this 
study.
After selection and randomization of patients with type 
2 diabetes, premixed insulin analogues were replaced 
with three doses of insulin aspart applied before main 
meals, and one dose of insulin detemir at bedtime, and 
followed for 52  weeks. Administration of metformin if 
not contraindicated was proceeded. A dose adjustment of 
insulin detemir and insulin aspart was performed accord-
ing to glucose profile based on self-monitoring measure-
ment and HbA1c level.
All recruited patients went through a comprehensive 
educational program, and became familiar with meal 
planning, exercising (compatible with their physical con-
dition), glucose self-monitoring on regular basis four 
times per day, as well as with insulin dose adjustment 
according to American Diabetes Association (ADA) 
guidelines [35]. Preinclusion data was obtained retro-
spectively from medical records.
Clinical measurements
All examinations were performed in the morning after an 
overnight fasting period by the same research nurses and 
physician-at the baseline visit on both, T2DM patients 
and healthy controls, and after 52 weeks only on T2DM 
patients. Body weight was measured using a balanced-
beam scale and was expressed in kilograms (kg). Height 
was measured using a wall-mounted stadiometer and 
expressed in centimeters (cm). Body mass index (BMI) 
was calculated based on these measures as kilograms 
per square meter (kg/m2). Blood pressure was measured 
on the right arm after a resting period of 10 min in a sit-
ting position with a mercury sphygmomanometer and 
expressed in millimeters of mercury (mmHg). Venous 
blood samples were collected for determination of bio-
chemistry, lipid profile status and HbA1c, both on base-
line and after a 52 week treatment period. Blood samples 
for DNA isolation and DBH and COMT gene polymor-
phism genotyping were taken at the end of the 52 week 
study period.
HbA1c was measured spectrophotometrically by turbi-
dimetric immuno inhibition (Olympus AU600 Beckman 
Coulter, USA). Glucose, cholesterol and triglycerides 
in serum were measured by an enzymatic colorimetric 
method.
Written informed consent was obtained from all par-
ticipants, after explaining the aims and procedures of the 
study, under guidelines approved by Ethics committee of 
the University of Zagreb School of Medicine and Clinical 
Hospital Merkur Zagreb. All studies have been carried 
out with the full cooperation of participants, adequate 
understanding, and have therefore been performed in 
accordance with the ethical standards of the Declaration 
of Helsinki.
Molecular genetic analyses
DNA was isolated from whole blood using DNeasy 
Blood and Tissue Kit (Qiagen, Chatsworth, CA) accord-
ing to manufacturer’s instructions. DNA extraction and 
genotyping were performed at Department for Func-
tional Genomics, Center for Translational and Clinical 
Research, University of Zagreb School of Medicine, Croa-
tia and at the Laboratory for Molecular Neuropsychiatry, 
Division of Molecular Medicine, Rudjer Boskovic Insti-
tute, Zagreb, Croatia. COMT Val108/158Met (rs4680) 
and DBH-1021C/T (rs1611115) polymorphisms were 
determined by ABI Prism 7300 Real time PCR System 
apparatus (Applied Biosystems, Foster city, California, 
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USA), according to the procedures described by Applied 
Biosystems. The primers and probes were purchased 
from Applied Biosystems as  TaqMan® Drug Metabo-
lism Genotyping Assay (C_25746809_50 for COMT) or 
 TaqMan® SNP Genotyping Assay (C_2535786_10 for 
DBH). All genotyping procedures were done blindly to 
clinical data. As a quality control for genotyping analyses, 
5% of all samples were genotyped again.
Statistical analysis
Baseline data was reported using descriptive statistics. 
The results, expressed as means (x) ± standard deviation 
(SD) or medians, were evaluated with Sigma Stat 3.5 (Jan-
dell Scientific Corp. San Raphael, California, USA) using 
one-way and repeated measures analysis of variance 
(ANOVA) and t test, or with Kruskal–Wallis ANOVA on 
ranks, Mann–Whitney test, and Wilcoxon Signed Rank 
Test, when the normality of the data failed. The Hardy–
Weinberg analysis was used to test the equilibrium of the 
population. The differences in the genotype frequencies 
were evaluated using the Chi square test. The level of sig-
nificance was set to p value less than 0.05.
Results
Demographics
Demographic data for all 185 patients (70 male, 115 
female) and 156 healthy controls (52 male, 104 female) 
are shown in Table 1. The mean age of studied population 
was 67.1 ± 8.01 years, with a mean duration of diabetes 
16.2 ± 5.95 years. The mean age of healthy controls was 
44.1 ± 11.6 years. Patients were treated with premix insu-
lin analogues for a mean duration of 5.7 ± 2.8 years (time 
from initiation of insulin therapy to inclusion into this 
study), and were on an average daily dose of 0.72 Units/
kg (Table 1).
In patients with type 2 diabetes, a significant differ-
ence between HbA1c values [median 8.5 (min 6.2–max 
12.8) vs. 7.7% (min 5.1–max 11.9) (69 vs. 61  mmol/
mol); T = 1861; p < 0.001; Wilcoxon Signed Rank Test] 
and between fasting plasma glucose values [median 11.3 
(min 5.2–max 21.3) vs. 8.2 (min 4.4–max 17.7) mmol/L; 
T  =  972; p  <  0.001; Wilcoxon Signed Rank Test] was 
observed, determined at baseline and at the end of the 
52 week follow up period (Fig. 1). HbA1c values and fast-
ing plasma glucose values were significantly decreased 
after 52 weeks of treatment compared to baseline values. 
At the end of the follow up period, 28.1% of patients on 
intensified insulin regimen with treatment of three times 
daily of insulin aspart and insulin detemir at bedtime, 
achieved HbA1c  <  7.0% (<  53  mmol/mol). This reduc-
tion was obtained with a mean dose of 0.44 ± 0.19 Units/
kg insulin aspart and 0.41  ±  0.16 Units/kg of insulin 
detemir, respectively. There was no significant decrease 
in BMI values in the whole patient list [median 30.04 
(min 20.66–max 52.6) vs. 29.76 (min 22.55–max 47.26) 
kg/m2; T = 3944; p = 0,312; Wilcoxon Signed Rank Test] 
(Fig. 1c), or between female or male patients.
As expected, there was a significant difference in the 
BMI between patients [median 30.04 (min 20.66–max 
52.6) kg/m2] and healthy controls [median 25.30 (min 
15.6–max 54.00) kg/m2]; and in fasting plasma glucose 
values in T2DM patients [median 11.3 (min 5.2–max 
21.3) mmol/l] vs. healthy controls [median 5.1 (min 4.00–
max 6.90) mmol/l], (p < 0.001, Mann–Whitney test).
Table 1 Demographic data for 185 patients with type 2 diabetes
BW body weight, BMI body mass index
Variable Descriptive statistics
Mean Median Minimum Maximum Std. dev.
Age (years) 67.11 67.00 43.00 85.00 8.01
BW (kg) at baseline 84.13 83.00 54.00 128.00 13.94
BW after 52 weeks (kg) 83.78 83.00 55.00 120.00 13.32
BMI (kg/m2) at baseline 30.37 30.04 20.66 52.60 4.58
BMI after 52 weeks (kg/m2) 30.23 29.76 22.55 47.26 4.31
HBA1c (%) at baseline 8.58 8.50 6.20 12.80 1.02
HBA1c after 52 weeks (%) 7.78 7.70 5.10 11.90 1.11
Fasting glucose levels at baseline (mmol/L) 11.74 11.30 5.20 21.30 2.81
Fasting glucose levels after 52 weeks (mmol/L) 8.73 8.20 4.40 17.70 2.37
Detemir dose (units/day) 34.39 32.00 5.00 120.00 14.84
T2DM duration (years) 16.15 16.00 3.00 38.00 5.95
Premix dose (IU/day) 60.51 56.00 22.00 180.00 22.44
Detemir dose per kg (units/kg/day) 0.41 0.38 0.08 1.30 0.16
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Weight change due to insulin therapy
Based on the difference in weight change in response 
to therapy, patients were divided into three groups: 
groups with weight gain, weight reduction or no change 
in weight after the 52-week follow up period. After 
52  weeks, a body weight reduction (3.4  ±  3.2  kg) was 
observed in 73 patients (39.5%); no change in body 
weight was found in 52 patients (28.1%); and 60 patients 
(32.4%) gained weight (3.3 ± 2.2 kg). The results revealed 
that the weight change and the starting BMI values were 
inversely proportional, since the group who lost weight 
had the highest starting BMI [mean 31.2 ±  5.2; median 
30.35 (min 23.18–max 52.60) kg/m2], while the observed 
group who gained weight had the lowest starting BMI 
[mean 29.1 ± 4.2; median 29.21 (min 20.66–max 40.01) 
kg/m2]. The difference in BMI between these two groups 
was significant (U = 1725; p = 0.036; Mann–Whitney U 
test).
In order to explore the association of starting BMI with 
weight loss due to treatment, patients were addition-
ally subdivided into four groups depending on the start-
ing BMI (BMI < 27, 39 patients; BMI 27–29, 33 patients; 
BMI 29–31, 42 patients; BMI  >  31, 71 patients). The 
change in HbA1c value was significant in all four groups 
of patients. The group with the lowest BMI (BMI  <  27) 
needed significantly lower doses of insulin detemir per kg 
than other groups [median 0.32 (min 0.13–max 0.77) vs. 
median 0.4 (min 0.085–max 1.30) Units/kg] (U =  1215; 
p < 0.001 Mann–Whitney U test) to obtain adequate gly-
cemic control.
Association between COMT Val108/158Met 
and DBH‑1021C/T polymorphisms and clinical parameters
No significant deviation from the Hardy–Weinberg equi-
librium was found for either COMT Val108/158Met 
(χ2 = 1.602) or DBH-1021C/T (χ2 = 0.079) genotypes.
The frequency of the COMT Val108/158Met or DBH-
1021C/T genotypes in T2DM patients and in healthy 
control subjects is presented in Table  2. The frequency 
of the COMT Val108/158Met (χ2 = 0.389; p = 0.824) or 
DBH-1021C/T (χ2 = 0.097; p = 0.952) genotypes did not 
differ significantly between healthy controls and patients 
with type 2 diabetes. A similar genotype distribution 
was found between female patients and female controls 
for COMT Val108/158Met (χ2 =  0.853; p =  0.653) and 
DBH-1021C/T (χ2  =  0.100; p  =  0.951) genotypes, and 
between male patients and male controls for COMT 
Val108/158Met (χ2  =  0.147; p  =  0.929) and DBH-
1021C/T (χ2 = 1.041; p = 0.594) genotypes, respectively 
(Table 2).
Fig. 1 Changes in HbA1c, fasting plasma glucose values, and BMI 
due to 52‑weeks of treatment. Central box represents the values 
from the lower to upper quartile and the middle line represents 
the median. The horizontal line extends from the minimum to the 
maximum value (non‑outlier range) and the “far out” values (outliers) 
are displayed as separate points: a changes in HbA1c due to 52‑week 
of treatment; b changes in fasting plasma glucose values due to 
52‑week of treatment; c changes in BMI due to 52‑week of treatment. 
***p < 0.001 vs. the baseline values
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There were no significant differences in the BMI values, 
body weight, fasting plasma glucose, or HbA1c in T2DM 
patients subdivided into carriers of the AA, GA and 
GG genotypes of the COMT Val108/158Met (Table  3), 
or when patients were subdivided into carriers of the 
CC, CT and TT of the DBH-1021C/T (Table  3), nei-
ther at baseline nor after 52 week treatment with insulin 
detemir. In healthy control subjects no significant differ-
ences were detected in BMI, body weight or fasting glu-
cose values when subjects were subdivided into carriers 
of the COMT Val108/158Met AA, GA and GG geno-
types or carriers of the DBH-1021C/T CC, CT and TT 
genotypes (Additional file 1: Table S1).
Although there was no significant association between 
COMT Val108/158Met polymorphism and changes in 
BMI, body weight, fasting glucose levels and HbA1c, 
patients with T2DM were additionally subdivided into 
COMT Val108/158Met A carriers (i.e. subjects carrying 
the combined AG and AA genotypes) vs. GG homozy-
gotes. COMT A carriers achieved significantly better 
HbA1c values after the 52  week treatment compared to 
patients carrying the GG genotype (A carriers: mean 7.55% 
(59  mmol/mol); median 7.70% (min 5.10–max 10.50) vs. 
GG genotype: mean 8.10% (65 mmol/mol) median 8.00% 
(min 5.80–max 11.90) (U  =  2466.5; p  =  0.029; Mann–
Whitney test)) (Fig. 2a, b). This difference was not gender 
dependent. Among patients who had HbA1c-decrease 
over 1% and achieved HbA1c  <  7% (<  53  mmol/mol), 
the GG genotype of the COMT was less frequently pre-
sent when compared to the patients with higher levels of 
HbA1c (χ2 = 4.2879; p = 0.039; χ2 test) (Fig. 2c).
Although a visible trend of unfavorable clinical values 
in correlation with DBH TT genotype was observed, 
DBH-1021C/T genotypes were not significantly asso-
ciated with any of the measured variables, possibly due 
to low frequency of this particular genotype (Additional 
file 1: Table S2).
Discussion
This study revealed that A carriers (i.e. the combined AA 
and AG genotype) of the COMT Val108/158Met poly-
morphism achieved significantly better HbA1c values 
after 52  weeks of treatment, compared to patients with 
T2DM carrying GG genotype. Although we expected to 
detect the association of COMT Val108/158Met and/or 
DBH-1021C/T polymorphism with the effectiveness of 
insulin detemir in achieving glucose control and body 
weight control, our results did not confirm any other sig-
nificant association with BMI, body weight or fasting glu-
cose values in patients with T2DM.
In our study, COMT Val108/158Met or DBH-1021C/T 
polymorphisms were not associated with T2DM. These 
data do not agree with a significant association found 
between COMT Val108/158Met and T2DM [36]; how-
ever this association was detected in the Asian popula-
tion, which could have additional confounding factors. 
In contrast to our results, in a large Caucasian popula-
tion COMT Val108/158Met was associated with T2DM 
[29], while DBH-1021C/T was significantly associated 
with T2DM and other clinical phenotypes responsive to 
peripheral sympathetic tone in a tissue-specific manner 
[37], implying that present study lacked the statistical 
power or the needed sample size to detect these associa-
tions. However, this was not the main goal of the study, 
since we evaluated the possible association between 
COMT Val108/158Met and DBH-1021C/T polymor-
phisms and detemir-induced control of glucose control 
and body weight.
Subjects diagnosed with T2DM have a two- to fourfold 
higher chance of developing a serious cardiovascular out-
come compared to those without diabetes [38]. Weight 
gain is one of the major problems associated with insu-
lin therapy. The vast majority of patients with T2DM are 
resistant to insulin and have associated significant cardi-
ovascular risk factors. Hyperglycemia is considered as a 
Table 2 Distribution of the COMT Val108/158Met and DBH-1021C/T genotypes in patients with type 2 diabetes (T2DM 
patients) and healthy controls, and in subjects subdivided according to gender
COMT Val108/158Met DBH‑1021C/T
T2DM/controls AA AG GG CC CT TT
T2DM patients 39 (21.1%) 101 (54.6%) 45 (24.3%) 113 (61.1%) 64 (34.6%) 8 (4.3%)
Healthy controls 36 (23.1%) 80 (51.3%) 40 (25.6%) 94 (60.3%) 56(35.9%) 6 (3.8%)
χ2 test χ2 = 0.389; df = 2; p = 0.824 χ2 = 0.097; df = 2; p = 0.952
T2DM women 25 (21.7%) 61 (53.1%) 29(25.2%) 68 (59.1%) 42 (36.5%) 5 (4.4%)
Healthy women 27 (26%) 49 (47.1%) 28 (26.9%) 63 (60.6%) 36 (34.6%) 5 (4.8%)
χ2 test χ2 = 0.853; df = 2; p = 0.653 χ2 = 0.100; df = 2; p = 0.951
T2DM men 14 (20%) 40 (57.1%) 16 (22.9%) 45 (64.3%) 22 (31.4%) 3 (4.28%)
Healthy men 9 (17.3%) 31 (59.6%) 12 (23.1%) 31 (59.6%) 20 (38.5%) 1 (1.9%)
χ2 test χ2 = 0.147; df = 2; p = 0.929 χ2 = 1.041; df = 2; p = 0.594
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principal cause of diabetic complications. Elevated blood 
glucose levels in patients with diabetes increases the rate 
of glycation, a nonenzymatic process of reducing sug-
ars with free amino groups of proteins, lipids and amino 
acids [39]. Glycated substances can be further modified 
in compounds called advanced glycation end products 
(AGE) which can trigger inflammatory reactions lead-
ing to atherosclerosis, kidney tissue damage, damage to 
small vessels in the eye and other major complications 
of diabetes acids [39]. Glycation is a process whose sig-
nificance has recently been revealed also in many other 
diseases, including neurodegeneration [40]. Although at 
lowered blood glucose levels the sugars will be released 
from the amino groups, it is argued that most of the risk 
factors can be successfully controlled but the contribu-
tion of decreasing hyperglycemia is lower than expected 
[41, 42]. Increment of 1% in HbA1c increased the risk of 
cardiovascular disease mortality by 53% in type 1 diabetic 
patients, but only by 7.5% in patients with T2DM [41, 
42]. Based on those data, it can hardly be expected that 
lowering of HbA1c of 1–2% alone is sufficient to signifi-
cantly decrease the mortality risk in people with T2DM 
[41, 43]. On the other hand, weight loss represents one 
of the main goals of therapy in overweight patients with 
T2DM [44]. Clinical studies demonstrate that therapeu-
tic benefit rises with increasing weight loss, but even 
losses as low as 0.45–4 kg have positive effects on meta-
bolic control, cardiovascular risk factors and mortality 
Table 3 Values of BMI, body weight, fasting glucose levels and HbA1c in in patients with type 2 diabetes (T2DM patients) 
subdivided into carriers of the COMT Val108/158Met and DBH-1021C/T genotypes
* Data are presented as median and minimum and maximum
At baseline After 52‑week treatment period
COMT 
Val108/158Met 
genotype (num‑
ber of patients)
AA (39) AG (101) GG (45) AA (39) AG (101) GG (45)
BMI (kg/m2) 29.41 (22.59–37.8) 30.02 (20.66–47.80) 30.04 (20.98–52.6) 29.28 (23.84–37.78) 30.10 (22.55–45.17) 29.39 (22.92–47.26)
Kruskal–Wallis 
ANOVA on Ranks
H = 0.137; df = 2; p = 0.934 H = 0.067; df = 2; p = 0.967
Body weight (kg) 85.00 (63.00–
106.00)
82.00 (54.00–
127.00)
84.00 (59.00–
128.00)
84.00 (64.00–
108.00)
83.00 (55.00–
120.00)
82.00 (59.00–115.00)
Kruskal–Wallis 
ANOVA on ranks
H = 0.662; df = 2; p = 0.719 H = 0.167; df = 2; p = 0.920
Fasting glucose 
levels (mmol/L)
12.30 (7.00–18.90) 11.00 (5.20–19.70) 11.70 (8.20–21.30) 8.40 (4.40–17.70) 8.10 (4.60–15.90) 8.10 (5.40–14.50)
Kruskal–Wallis 
ANOVA on ranks
H = 2.116; df = 2; p = 0.347 H = 0.397; df = 2; p = 0.820
HbA1c 8.4 (7.00–11.20) 8.4 (6.20–11.80) 8.5 (7.20–12.80) 7.7 (6.20–10.20) 7.6 (5.10–10.5) 8.00 (5.80–11.90)
Kruskal–Wallis 
ANOVA on ranks
H = 2.684; df = 2; p = 0.261 H = 4.965; df = 2; p = 0.084
At baseline After 52‑week treatment period
DBH‑1021C/T geno‑
type (number of 
patients)
CC (113) CT (64) TT (8) CC (113) CT (64) TT (8)
BMI (kg/m2) 29.88 (20.66–47.80) 30.04 (22.19–52.60) 34.26 (26.47–35.51) 30.10 (22.55–45.17) 29.40 (22.60–47.26) 30.86 (27.14–34.26)
Kruskal–Wallis 
ANOVA on ranks
H = 1.426; df = 2; p = 0.490 H = 1.018; df = 2; p = 0.601
Body weight (kg) 82.00 (58.00–
127.00)
84.50 (54.00–
128.00)
89.00 (72.00–
110.00)
82.00 (57.00–
120.00)
83.50 (55.00–
115.00)
87.00 (72.00–106.00)
Kruskal–Wallis 
ANOVA on ranks
H = 1.279; df = 2; p = 0.527 H = 1.403; df = 2; p = 0.498
Fasting glucose 
levels
11.10 (5.20–20.10) 11.5 (7.10–21.30) 11.9 (9.10–12.80) 8.25 (5.20–15.90) 8.25 (4.40–17.70) 7.10 (6.20–11,10)
Kruskal–Wallis 
ANOVA on ranks
H = 1.073; df = 2; p = 0.585 H = 0.373; df = 2; p = 0.830
HbA1c 8.50 (6.50–12.80) 8.40 (6.20–11.80) 8.65 (7.80–10.20) 7.70 (5.90–11.90) 7.8 (5.10–10.30) 7.7 (6.20–8.60)
Kruskal–Wallis 
ANOVA on ranks
H = 0.612; df = 2; p = 0.736 H = 0.302; df = 2; p = 0.860
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rates [44]. In the present study, at the end of the 52 week 
of treatment, the main cardiovascular risk factors were 
significantly reduced for patients with T2DM. There was 
a significant decline in mean HbA1c value and in mean 
fasting plasma glucose value, which corresponds to the 
fundamental function of insulin. We did not observe 
weight gain which could be expected due to insulin ther-
apy. These data agree with the previous known weight 
Fig. 2 Association between COMT Val108/158Met A‑carriers and clinical parameters: a Values of BMI, body weight, fasting glucose levels and 
HbA1c in T2DM patients subdivided into COMT Val108/158Met A‑carriers and GG homozygous group; *data are presented as median and 
minimum and maximum. b The change in HbA1c in subjects subdivided into the A‑carriers and GG homozygous genotype of the COMT 
Val108/158Met; central box represents the values from the lower to upper quartile and the middle line represents the median. The horizontal line 
extends from the minimum to the maximum value (non‑outlier range) and the “far out” values (outliers) are displayed as separate points; c differ‑
ence in the COMT Val108/158Met frequency in subjects subdivided according to the HbA1c decrease
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sparing effect of insulin detemir in comparison to other 
basal insulins [33, 45]. Zafar et  al. [45] showed a dose-
dependent weight gain of patients treated with insulin 
detemir. Since our patients had adjusted doses of detemir 
and aspart insulin, according to the glucose profile, it was 
not possible to detect a correlation between weight gain 
and insulin detemir dose. However, our results revealed 
that the group with the smallest BMI (BMI < 27) at base-
line needed significantly lower doses of insulin detemir 
than other groups to obtain adequate glycemic control.
Some of the known cardiovascular risk factors, 
such as obesity and hypertension, are in part geneti-
cally determined, but the entire array of specific genes 
remains unidentified [46]. Our results showed dif-
ferent patterns of weight change and differences in 
achieving adequate glucose control in patients treated 
for 52  weeks with insulin detemir. Since COMT 
Val108/158Met and/or DBH-1021C/T polymorphisms 
are implicated in cardiovascular, sympathetic, and 
endocrine pathways [37, 47], we expected that treat-
ment induced differences in weight change and glucose 
control might be associated with these polymorphisms. 
In line with other data that failed to show an associa-
tion of COMT polymorphisms with weight, BMI, or 
obesity risk [48, 49], no significant association between 
COMT Val108/158Met or DBH-1021C/T genotypes 
and the change in body weight was detected. Still, our 
data showed that patients with TT genotype of the 
DBH-1021C/T or with AA genotype of the COMT 
Val108/158Met achieved a slight BMI decline, since 
there was a trend that did not reach the level of statisti-
cal significance. These results are partly consistent with 
previous reports showing an association between GG 
genotype with a fat-BMI [29], and with a slight decrease 
in percentage of body fat in AA carriers [49]. Although 
an association of COMT Val108/158Met genotypes 
with abdominal obesity and high blood pressure was 
found in Swedish men, connecting AA genotype with 
a higher risk of abdominal obesity, they failed to find a 
significant correlation to BMI [27]. These results only 
underline the ambiguous impact of COMT polymor-
phism on obesity.
On the other hand, our results showed that patients 
with best glycemic response were predominantly COMT 
Val108/158Met A carriers (i.e. carriers of the combined 
AA and AG genotypes). They achieved significantly bet-
ter HbA1c values after the 52-week treatment com-
pared to patients carrying the GG genotype, pointing 
to the fact that presence of one or two A allele of the 
COMT Val108/158Met could be associated with a bet-
ter response to insulin detemir therapy. This finding dif-
fers from the data from a recent study that reported an 
association of the G allele with lower values of HbA1c 
[50], but is partly consistent with the results from a male 
obesity study in Denmark in which the GG genotype was 
associated with impaired glucose tolerance and high fat 
BMI [29, 50].
In our study, and in line with previous data [51], DBH-
1021C/T polymorphism was not associated with changes 
in BMI values, body weight, fasting plasma glucose, or 
HbA1c in T2DM patients, or with BMI, body weight and 
fasting glucose values in healthy controls. A preclinical 
study showed that DBH deficient mice exhibit hyperin-
sulinemia, lower plasma glucose levels, and insulin resist-
ance [52]. However, in our study there was no association 
between fasting glucose levels and DBH-1021C/T and/or 
COMT Val108/158Met polymorphisms.
Estrogen regulates COMT activity [53], and women 
have lower COMT enzymatic activity than men and 
genotype effect was more pronounced in males than in 
females [25]. In agreement with our previous results 
including 1058 healthy Caucasian subjects [54], a 
lack of gender dependent differences in the COMT 
Val108/158Met genotype frequency was detected in 
healthy controls, or in patients with T2DM (present 
study); and genotype effect was similar in both sexes. The 
differences with previous study [25], might be explained 
by the different diagnoses, different number and different 
ethnicities of subjects included.
In line with well-known effects of insulin detemir as a 
well-tolerated and effective long acting insulin [55], our 
data confirmed its highly beneficial weight sparing effect, 
especially in overweight patients, which is consistent 
with previous studies [34, 45], showing that treatment 
with insulin detemir was associated with less pronounced 
weight gain.
In conclusion, our results revealed that the presence 
of one or two A allele of the COMT Val108/158Met was 
associated with improved glycemic response, since the 
carriers of the combined AA and AG genotypes achieved 
significantly better HbA1c values after the 52-week insu-
lin detemir treatment compared to patients carrying the 
GG genotype. These data suggest a protective effect of 
the COMT Val108/158Met A allele and a better response 
in A carriers to insulin detemir therapy. As far as we are 
aware, this is the first study to reveal a lack of significant 
association between DBH-1021C/T and effectiveness of 
insulin detemir in achieving glucose control as well as 
body weight control.
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